Cytox
Developing transformational prognostic technology that may contribute to the assessment of an individual's risk of developing dementias such as Alzheimer's disease.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD21—32m (Dealroom.co estimates Jun 2017.)
Company register number 05149130
Oxford England (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
£600k | Seed | ||
£3.5m | Series A | ||
£1.5m | Series A | ||
N/A | £1.3m | Grant | |
£2.6m | Series B | ||
N/A | £800k | Grant | |
€50.0k | Grant | ||
Total Funding | AUD21.1m |
Recent News about Cytox
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.